查看更多
密码过期或已经不安全,请修改密码
修改密码壹生身份认证协议书
同意
拒绝
同意
拒绝
同意
不同意并跳过
参考文献:
[1] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(Suppl 4S):S117–S314.
[2] Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436–1446.
[3] The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117–127.
[4] Brata R et al. Hemodynamic Effects of SGLT2 Inhibitors in Patients with and without Diabetes Mellitus—A Narrative Review. Healthcare. 2024
[5] Tian Y et al. Dapagliflozin Improves Diabetic Kidney Disease by Inhibiting Ferroptosis through β-Hydroxybutyrate Production. Renal Failure. 2025
[6] Neal B, et al. Impact of SGLT2 inhibitors on Kidney Outcomes: Collaborative Meta-analysis of Large Trials. Lancet. 2022;400:1788-1801.
[7] Jongs N, et al. Effect of Dapagliflozin on Urinary Albumin Excretion in CKD.Lancet Diabetes Endocrinol. 2021;9:755-766.
审批编号:CN-161847
声明:仅供医疗卫生专业人士参考,不得转发或分享非医疗卫生专业人士。不得用于推广目的。这些资料可能含有未经许可的产品/适应证的信息,阿斯利康公司不建议您将产品用于未经许可的适应证。本文的撰稿/发布由阿斯利康提供支持。
查看更多